Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Stopped Due to lack of efficacy shown at the time of the interim analysis.
Conditions
- Thyroid Cancer
- Renal Cell Carcinoma
- Non Small Cell Lung Cancer
- Small-cell Lung Cancer
- Bladder Cancer
- Melanoma
- Merkel Cell Carcinoma
- Skin Squamous Cell Carcinoma
- Microsatellite Instability High
- Triple Negative Breast Cancer
- Mesothelioma
- Thymic Cancer
- Cervical Cancer
- Biliary Tract Cancer
- Hepatocellular Carcinoma
- Ovarian Cancer
- Gastric Cancer
- Head and Neck Squamous Cell Carcinoma
- Anal Cancer
Interventions
- DRUG: Nanrilkefusp alfa
- DRUG: Pembrolizumab
Sponsor
SOTIO Biotech AG
Collaborators